News

NORD Announces 2016 Rare Impact Award Recipients


 

References

The National Organization for Rare Disorders (NORD) will honor individuals and organizations for achievements to improve the lives of patients with rare diseases at its Rare Impact Awards celebration in Washington DC on Tuesday, May 17. Award recipients will be:

· Senator Orrin Hatch (R-UT)

· Representative Doris Matsui (D-CA)

· Arthur Caplan, PhD

· Stephen Cederbaum, MD

· The Friedreich’s Ataxia Research Alliance (FARA)

· Dawn Laney, MS, CGC, CCRC

· Desiree Lynn Howe

· Deborah Miller

· Noah Victoria

In addition, five companies will be honored for developing treatments for rare diseases that were approved by the FDA in 2015. Those companies are:

· Alexion Pharmaceuticals, Inc.

· Asklepion Pharmaceuticals, LLC

· Astellas Pharma

· United Therapeutics Corporation

· Wellstat Therapeutics Corporation

NORD hosts the awards celebration each year to highlight the achievements of legislators, rare disease clinicians and researchers, patient advocates, and others during the previous year. This year’s event will take place at the Warner Theatre in Washington DC and is open to all. Online registration, as well as information about sponsorship, is available on the NORD website.

Recommended Reading

EHR Report: How Zika virus reveals the fault in our EHRs
MDedge Family Medicine
Dr. Califf Is Confirmed as FDA Commissioner; NORD Issues Statement
MDedge Family Medicine
FDA Offers New Resource on Biosimilars for Health Care Providers
MDedge Family Medicine
IOM Report: Mitochondrial Replacement “Ethically Permissible”
MDedge Family Medicine
FDA Offers New Resource on Biosimilars for Health Care Providers (copy 1)
MDedge Family Medicine
Lupus patients’ transition to adult care leaves gaps, delays in care
MDedge Family Medicine
Early estrogen likely prevents bone fractures in Turner syndrome
MDedge Family Medicine
Topical allantoin cream speeds wound healing in epidermolysis bullosa
MDedge Family Medicine
Colombia reports first Zika deaths, all in medically compromised patients
MDedge Family Medicine
New hope for primary sclerosing cholangitis treatment
MDedge Family Medicine